FDA Approves Lumigan 0.01% as First-Line Therapy for the Reduction of Elevated IOP in Glaucoma Patients

Allergan, Inc. on the 31st August 2010 announced the United States Food and Drug Administration (FDA) has approved LUMIGAN(R) (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN(R) 0.01% is an optimized reformulation of LUMIGAN(R) (bimatoprost ophthalmic solution) 0.03%.

Previously it was announced on 9th March 2010 that the European Medicines Agency (EMEA) had granted Marketing Authorisation for Lumigan 0.01% as first-line therapy for the reduction of elevated intraocular pressure (IOP) in adults with chronic open-angle glaucoma and ocular hypertension.

Copies of Allergan's press releases and additional information about Allergan is available on the World Wide Web at www.allergan.com